Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lianhua Qingwen plus standard of care versus placebo plus standard of care for mild to moderate COVID-19
ChiCTR2200056727Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2022
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing LHQW group with Placebo group (2 arms). Primary endpoint: Median time to sustained improvement or resolution of 9 major symptoms. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
Lianhua Qingwen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200056727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056727.